<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JGP</journal-id>
<journal-id journal-id-type="hwp">spjgp</journal-id>
<journal-id journal-id-type="nlm-ta">J Geriatr Psychiatry Neurol</journal-id>
<journal-title>Journal of Geriatric Psychiatry and Neurology</journal-title>
<issn pub-type="ppub">0891-9887</issn>
<issn pub-type="epub">1552-5708</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0891988713481267</article-id>
<article-id pub-id-type="publisher-id">10.1177_0891988713481267</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Apathy in Patients With Parkinson Disease as a Function of Side of Onset</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Harris</surname>
<given-names>Erica</given-names>
</name>
<degrees>PhD, MPH</degrees>
<xref ref-type="aff" rid="aff1-0891988713481267">1</xref>
<xref ref-type="corresp" rid="corresp1-0891988713481267"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>McNamara</surname>
<given-names>Patrick</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff2-0891988713481267">2</xref>
<xref ref-type="aff" rid="aff3-0891988713481267">3</xref>
<xref ref-type="aff" rid="aff4-0891988713481267">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Durso</surname>
<given-names>Raymon</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff2-0891988713481267">2</xref>
<xref ref-type="aff" rid="aff3-0891988713481267">3</xref>
</contrib>
</contrib-group>
<aff id="aff1-0891988713481267">
<label>1</label>Department of Behavioral Sciences and Epidemiology, Naval Health Research Center, San Diego, CA, USA</aff>
<aff id="aff2-0891988713481267">
<label>2</label>Department of Neurology, Boston University School of Medicine, Boston, MA, USA</aff>
<aff id="aff3-0891988713481267">
<label>3</label>Department of Neurology, VA Boston Healthcare System, Boston, MA, USA</aff>
<aff id="aff4-0891988713481267">
<label>4</label>Northcentral University, 10000 University Dr., Prescott Valley, AZ, USA </aff>
<author-notes>
<corresp id="corresp1-0891988713481267">Erica Harris, Naval Health Research Center, Behavioral Sciences and Epidemiology (163), 140 Sylvester Road, San Diego, CA, 92106, USA. Email: <email>Erica.Harris@med.navy.mil</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>6</month>
<year>2013</year>
</pub-date>
<volume>26</volume>
<issue>2</issue>
<fpage>95</fpage>
<lpage>104</lpage>
<history>
<date date-type="received">
<day>24</day>
<month>10</month>
<year>2012</year>
</date>
<date date-type="rev-recd">
<day>29</day>
<month>1</month>
<year>2013</year>
</date>
<date date-type="accepted">
<day>30</day>
<month>1</month>
<year>2013</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2013</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<sec>
<title>Background:</title><p>In previous studies among patients with Parkinson disease (PD) who were administered the Apathy Evaluation Scale (AES), between 12% and 51% evidenced clinically significant apathy. Although apathy is a risk factor for dementia, its causes and clinical correlates have not been adequately studied. In particular, side of onset of disease, though a likely predictor of apathy and dementia, has not been thoroughly investigated.</p></sec>
<sec>
<title>Methods:</title><p>A total of 30 mid-stage patients with PD and 35 community-dwelling elderly control patients (CPs) were administered the AES (self version) along with a battery of cognitive and neuropsychiatric assessments. Persons close to patients with PD and CPs completed the AES—other (informant) version about the patient or CP. Multiple linear regression analysis examined predictors of apathy severity after controlling for mood, levodopa dosage equivalents (LDEs), gender, age, and disease severity (Hoehn–Yahr [H-Y] stage).</p></sec>
<sec>
<title>Results:</title><p>Patients with right-onset disease more frequently exhibited apathy and evidenced significantly higher total AES scores than left-onset patients with PD or CPs (<italic>P</italic> &lt; .03). Of all the patients, 42% with right-onset PD versus 11.1% of the patients with left-onset PD exhibited clinically significant levels of apathy. There were no differences for self versus informant scores for right-onset patients with PD. The AES scores were not correlated with depression, stress, anxiety, LDEs, gender, age, and H-Y stage. There were no gender differences for any AES variables.</p></sec>
<sec>
<title>Conclusion:</title><p>Clinically significant levels of apathy are much more likely to occur in patients with right-onset disease. These patients may be at greater risk of PD-related dementia.</p></sec>
</abstract>
<kwd-group>
<kwd>apathy</kwd>
<kwd>Parkinson’s disease</kwd>
<kwd>dopamine</kwd>
<kwd>side of onset</kwd>
<kwd>dementia</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0891988713481267">
<title>Introduction</title>
<p>Apathy is a measurable reduction in performing voluntary, goal-directed behaviors<sup><xref ref-type="bibr" rid="bibr1-0891988713481267">1</xref></sup>
<sup>,</sup>
<sup><xref ref-type="bibr" rid="bibr2-0891988713481267">2</xref></sup> and is usually indicative of lesions or dysfunctions within the frontal lobes, the basal ganglia, or the frontal basal ganglia systems.<sup><xref ref-type="bibr" rid="bibr2-0891988713481267">2</xref></sup>
<sup>,</sup>
<sup><xref ref-type="bibr" rid="bibr3-0891988713481267">3</xref></sup> Impairment of these systems is notable, especially because the basal ganglia structures enable the self to plan, to initiate, to execute, and to control self-generated intentional behavior<sup><xref ref-type="bibr" rid="bibr2-0891988713481267">2</xref></sup>
<sup>,</sup>
<sup><xref ref-type="bibr" rid="bibr3-0891988713481267">3</xref></sup> via communication with pathways leading to the frontal lobes in addition to monitoring the flow of internal and external information.<sup><xref ref-type="bibr" rid="bibr3-0891988713481267">3</xref></sup> Dysfunction can arise at any of these stages and produce apathy.<sup><xref ref-type="bibr" rid="bibr3-0891988713481267">3</xref></sup> Although apathy is frequently associated with depression, it can occur in the absence of depression<sup><xref ref-type="bibr" rid="bibr3-0891988713481267">3</xref><xref ref-type="bibr" rid="bibr4-0891988713481267"/>–<xref ref-type="bibr" rid="bibr5-0891988713481267">5</xref></sup> and is a potent predictor of dementia.<sup><xref ref-type="bibr" rid="bibr6-0891988713481267">6</xref></sup>
<sup>,</sup>
<sup><xref ref-type="bibr" rid="bibr7-0891988713481267">7</xref></sup> Furthermore, the development of apathy significantly impedes self-care and compliance with treatment regimens.</p>
<p>Studies utilizing the most commonly used apathy assessment instrument—the Apathy Evaluation Scale (AES)—have found the percentage of patients with Parkinson disease (PD) who have apathy range from a low of 12%<sup><xref ref-type="bibr" rid="bibr8-0891988713481267">8</xref></sup> to a high of 51%.<sup><xref ref-type="bibr" rid="bibr9-0891988713481267">9</xref></sup> Clinical correlates of apathy have not been adequately studied, and only one study could be found in the current literature examining side of onset effects with respect to apathy. Cubo et al<sup><xref ref-type="bibr" rid="bibr10-0891988713481267">10</xref></sup> administered the Lille Apathy Rating Scale (LARS) in their ANIMO study of early-stage patients with PD. They found that 33.4% of their sample (a total of 186 patients) were diagnosed with apathy only and 38.6% (215 patients) were diagnosed with apathy and depression. Apathy was higher among those patients who also had depression and were taking antidepressants. They also found apathy to be associated with greater motor symptom severity. Patients with right-onset disease, patients’ whose motor symptoms began on the right side, indicating greater left hemisphere pathology, had higher odds of developing apathy. In addition, neuroimaging studies of apathy in PD suggest side of onset should be strongly associated with the presence and degree of apathy in PD. High levels of apathy in mid-stage patients with PD are correlated with low gray matter density in the following brain areas: bilateral precentral gyrus, bilateral inferior parietal gyrus, bilateral inferior frontal gyrus, bilateral insula, right posterior cingulate gyrus, and right precuneus.<sup><xref ref-type="bibr" rid="bibr4-0891988713481267">4</xref></sup>
<sup>,</sup>
<sup><xref ref-type="bibr" rid="bibr11-0891988713481267">11</xref></sup>
<sup>,</sup>
<sup><xref ref-type="bibr" rid="bibr12-0891988713481267">12</xref></sup>
</p>
<p>In the present study, the AES was used to measure levels of apathy in patients with PD. In particular, side of onset differences were examined given the Cubo et al<sup><xref ref-type="bibr" rid="bibr10-0891988713481267">10</xref></sup> recent findings. It was hypothesized that patients with PD would have higher levels of apathy than community dwelling control patients (CPs). In particular, patients with right-onset disease would have greater levels of apathy and poorer cognition.</p>
</sec>
<sec id="section2-0891988713481267" sec-type="methods">
<title>Methods</title>
<p>A total of 30 mid-stage patients with PD (6 females) were recruited from the Parkinson/Movement Disorders Clinic at the VA Boston Healthcare System, Boston, Massachusetts. Dr Raymon Durso, director of the clinic, made all the diagnoses. The United Kingdom (UK) Parkinson’s Disease Society Brain Bank has established the following clinical diagnostic criteria: the patient must display at least 2 motor symptoms including bradykinesia and at least 1 of the following symptoms: cogwheeling, a resting tremor between 4 and 6 Hz, and postural instability.<sup><xref ref-type="bibr" rid="bibr13-0891988713481267">13</xref></sup> None of the patients were demented according to clinical examinations and <italic>Diagnostic and Statistical Manual of Mental Disorders</italic> (Fourth Edition, Text Revision) <sup><xref ref-type="bibr" rid="bibr14-0891988713481267">14</xref></sup> criteria. All patients (except for 1 female) were on some form of dopaminergic medication and were tested while on medications. All patients who were on dopaminergic medication had a beneficial response to either levodopa or a dopamine agonist. The 1 patient who was not on dopaminergic mediation had stopped taking the drug due to side effects. A group of 35 community-dwelling CPs (18 females) were also recruited from the VA community who were screened thoroughly for previous alcohol or drug abuse and history of mental illness. All of the CPs had some form of chronic illness such as high blood pressure, diabetes, a form of chronic pain (eg, back pain), and the like. Listed below are the neuropsychological tests that were administered to all the participants. All appropriate institutional review board (IRB) permissions were obtained from the local review boards, and all participants provided informed consent to participate in the study.</p>
<sec id="section3-0891988713481267">
<title>Levodopa Dosage Equivalents</title>
<p>The neurologist (R.D.) obtained all medication information from each patient. Levodopa dosage equivalents (LDEs) were calculated for all the patients based on previous studies<sup><xref ref-type="bibr" rid="bibr15-0891988713481267">15</xref></sup> with (regular levodopa dose + [controlled-release levodopa dose × 0.75] × 0.25) with catechol-<italic>O</italic>-methyltransferase inhibitor. Pramipexole dose × 0.67 and pergolide dose × 100.</p>
</sec>
<sec id="section4-0891988713481267">
<title>Side of Onset Measure</title>
<p>Side of disease onset was evaluated by self-report and review of the patient’s medical chart. Side of onset was confirmed by administering the revised version of the Unified Parkinson’s Disease Rating Scale (UPDRS).<sup><xref ref-type="bibr" rid="bibr16-0891988713481267">16</xref></sup>
<sup>,</sup>
<sup><xref ref-type="bibr" rid="bibr17-0891988713481267">17</xref></sup> A total UPDRS score was calculated for each patient. An asymmetry score was calculated by adding up the total of the right-sided items minus the left-sided items of the UPDRS. If a positive score resulted, greater right-sided disease was inferred, and if the difference score was negative, it indicated greater left-sided disease. These asymmetry scores for the side of onset were consistent in all cases with patient’s self-report or medical chart as verified by the neurologist (R.D.).</p>
</sec>
<sec id="section5-0891988713481267">
<title>Mini-Mental State Examination</title>
<p>Participants were administered the Mini-Mental State Examination (MMSE)<sup><xref ref-type="bibr" rid="bibr18-0891988713481267">18</xref></sup> to obtain a baseline cognitive level of functioning with a cutoff score of &lt;25 to rule out any possible dementia.</p>
</sec>
<sec id="section6-0891988713481267">
<title>Parkinson Disease-Cognitive Rating Scale</title>
<p>Participants were administered the Parkinson Disease-Cognitive Rating Scale (PD-CRS).<sup><xref ref-type="bibr" rid="bibr19-0891988713481267">19</xref></sup> The PD-CRS is a diagnostic tool used to cognitively assess cortical and frontal–subcortical deficits in patients with PD. It was developed such that Parkinson Disease Dementia (PDD) could be diagnosed prior to it manifesting in patients. The PD-CRS consists of the following subcortical test components including attention, working memory, alternating and action fluencies, immediate and delayed verbal memory, and clock drawing. There are 2 cortical test components comprising naming and copying a clock. The PD-CRS has 94% sensitivity and specificity to diagnose PDD, high internal consistency with Cronbach α = .85, excellent construct validity, test–retest, and inter-rater reliability. A score of ≤64 indicates cognitive impairment.</p>
</sec>
<sec id="section7-0891988713481267">
<title>Depression Anxiety Stress Scales</title>
<p>The short form of the Depression Anxiety Stress Scales (DASS<sub>21</sub>) developed by Lovibond and Lovibond<sup><xref ref-type="bibr" rid="bibr20-0891988713481267">20</xref></sup> was administered. The DASS<sub>21</sub> has been used successfully in studies of patients with PD.<sup><xref ref-type="bibr" rid="bibr21-0891988713481267">21</xref><xref ref-type="bibr" rid="bibr22-0891988713481267"/>–<xref ref-type="bibr" rid="bibr23-0891988713481267">23</xref></sup> It consists of 21 items with 7 questions each in the domains of depression, anxiety, and stress. Participants were instructed to indicate on a scale of 0 (<italic>did not apply to me at all</italic>) to 3 (<italic>applied most of the time</italic>), the extent to which each statement applied to them over the last week. Antony et al<sup><xref ref-type="bibr" rid="bibr24-0891988713481267">24</xref></sup> and Crawford and Henry<sup><xref ref-type="bibr" rid="bibr25-0891988713481267">25</xref></sup> have previously reported high reliability, validity, and other psychometric properties for the DASS subscales. Since the short form of the DASS was administered, the DASS manual<sup><xref ref-type="bibr" rid="bibr20-0891988713481267">20</xref></sup> reports that all scores are to be doubled to compare them adequately for the cutoff scores of depression (normal = 0-9, mild = 10-13, moderate = 14-20, severe = 21-27, and extremely severe = 28+), anxiety (normal = 0-7, mild = 8-9, moderate = 10-14, severe = 15-19, and extremely severe = 20+), and stress (normal = 0-14, mild = 15-18, moderate = 19-25, severe = 26-33, and extremely severe = 34+). The CPs reported scores within normal ranges for all of the DASS<sub>21</sub> subscales.</p>
</sec>
<sec id="section8-0891988713481267">
<title>Stroop Color-Word Interference Test</title>
<p>All participants were administered the Golden version of the Stroop Color–Word Interference Test.<sup><xref ref-type="bibr" rid="bibr26-0891988713481267">26</xref></sup> In this version, the participants have 45 seconds to read as many words or colors as they can on each test page. There are 3 test pages. The first page consists of the word reading page whereby participants read colors (red, green, or blue) that are printed in capitals and are in black ink. Next is the color naming page that consists of a series of XXXX printed in different colors (red, green, or blue) that participants are to read. The inhibition page is last whereby participants are presented color words that are printed in an incongruent ink color. For example, the word “RED” is printed in blue ink. The participant is required to inhibit the tendency to read the word and instead read the color of ink. The primary measure for each of the 3 test conditions was the number of words read in 45 seconds. Lower scores indicate greater impairment.</p>
</sec>
<sec id="section9-0891988713481267">
<title>Apathy Evaluation Scale</title>
<p>The AES<sup><xref ref-type="bibr" rid="bibr1-0891988713481267">1</xref></sup> consists of self (patient), examiner, and informant (other) versions. All participants completed the self version via self-report and also had a significant other or a close friend to complete the informant version about them. There are a total of 18 questions evaluating 4 domains of apathy and a global score of apathy (based on a one month retrospective evaluation). The 4 domains include cognitive, behavior, emotional, or “other.” The cognitive domain refers to a reduction in the expression of the number of intentions toward goal-directed behaviors. The behavioral domain is a reduction in the number of observable goal-directed behaviors. The emotional domain assesses a reduction in the number of displays of emotion.<sup><xref ref-type="bibr" rid="bibr27-0891988713481267">27</xref></sup> The “other” domain assesses the awareness level of the patient with respect to a lack of motivation and initiative. Answers are based on a 4-point Likert-type scale (1 = <italic>not at all characteristic</italic> to 4 = <italic>very characteristic</italic>) with the maximum score being 72 and the minimum score being 18. Previous studies indicate a cutoff off score of ≥38 as indicative of clinical apathy.<sup><xref ref-type="bibr" rid="bibr28-0891988713481267">28</xref></sup>
<sup>,</sup>
<sup><xref ref-type="bibr" rid="bibr29-0891988713481267">29</xref></sup>
</p>
</sec>
<sec id="section10-0891988713481267">
<title>Statistical Analysis</title>
<p>All statistical analyses were conducted using SPSS, version 18.0 (IBM, Chicago, IL). Preliminary analyses revealed that all background and clinical variables were non-normally distributed. A Kruskal-Wallis test was performed with appropriate Mann-Whitney <italic>U</italic> pairwise comparisons to evaluate group differences in non-normally distributed data. Hierarchical logistic regression analyses were performed to calculate the odds ratios (ORs) to examine whether having right- versus left-onset PD is more likely to predict developing a type of apathy. Predictors included age, gender, and disease duration in step 1. In step 2, side of onset was entered. Apathy scores were dichotomized according to the mean apathy score for each type of apathy. Having right-versus left-onset PD was also dichotomized. A multiple linear regression analysis examined which background and clinical variables were predictors of total AES scores for the patient group. The analyses were performed using side of onset, disease severity (Hoehn–Yahr [H-Y] stage), gender, and DASS<sub>21</sub> total score as predictor variables, and the AES total score was the criterion variable. A Wilcoxon Signed Rank Test for correlated samples examined differences between self and informant (other) responses on the AES. Spearman ρ correlations were applied to examine the relationships among background variables and all patient apathy domains and total scores. Bonferroni corrections were applied to account for multiple comparisons for the analysis of variance.</p>
</sec>
</sec>
<sec id="section11-0891988713481267">
<title>Results</title>
<p>
<xref ref-type="table" rid="table1-0891988713481267">Table 1</xref> presents the demographic, cognitive, and mood data of patients with PD and CPs.</p>
<table-wrap id="table1-0891988713481267" position="float">
<label>Table 1.</label>
<caption>
<p>Comparison of Demographic, Cognitive, and Mood Data for Patients With PD Versus CPs.</p>
</caption>
<graphic alternate-form-of="table1-0891988713481267" xlink:href="10.1177_0891988713481267-table1.tif"/>
<table>
<thead>
<tr>
<th> </th>
<th>Patients with PD (n = 30); Mean (SD)</th>
<th>CPs (n = 35); Mean (SD)</th>
<th>
<italic>P</italic> Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>65.83 (11.91)</td>
<td>58.17 (9.78)</td>
<td>.005<sup>b</sup>
</td>
</tr>
<tr>
<td>Gender (n, % female)</td>
<td>6 (20%)</td>
<td>18 (51.4%)</td>
<td>.16</td>
</tr>
<tr>
<td>Education, in years</td>
<td>14.60 (2.96)</td>
<td>16.13 (2.01)</td>
<td>.006<sup>b</sup>
</td>
</tr>
<tr>
<td>
<sup>a</sup>Handedness (n, % left handed)</td>
<td>3 (12%)</td>
<td>4 (12.1%)</td>
<td>.16</td>
</tr>
<tr>
<td>Disease duration, years</td>
<td>8.98 (5.54)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Disease stage</td>
<td>Stage II = 13 (15.4% females) Stage III = 15 (26.7% females) Stage IV = 2</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>H-Y stage</td>
<td>2.63 (0.62)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>LDE (mg/d)</td>
<td>586.13<sup>c</sup> (332.49)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>MMSE</td>
<td>27.80<sup>d </sup>(1.39)</td>
<td>28.87<sup>e</sup> (0.82)</td>
<td>.01<sup>b</sup>
</td>
</tr>
<tr>
<td>
<sup>j</sup>PD-CRS</td>
<td>88.43<sup>g</sup> (16.04)</td>
<td>100.00<sup>h </sup>(12.24)</td>
<td>.17</td>
</tr>
<tr>
<td>DASS<sub>21</sub>–stress</td>
<td>6.53 (4.87)</td>
<td>3.91 (3.27)</td>
<td>.04<sup>f</sup>
</td>
</tr>
<tr>
<td>DASS<sub>21</sub>–anxiety</td>
<td>5.40 (4.36)</td>
<td>1.89 (2.70)</td>
<td>.0001<sup>i</sup>
</td>
</tr>
<tr>
<td>DASS<sub>21</sub>–depression</td>
<td>4.90 (3.77)</td>
<td>2.23 (2.96)</td>
<td>.0001<sup>i</sup>
</td>
</tr>
<tr>
<td>DASS<sub>21</sub>–total</td>
<td>16.43 (12.12)</td>
<td>8.03 (6.83)</td>
<td>.002<sup>b</sup>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0891988713481267">
<p>Abbreviations: NA, not applicable; LDE, levodopa dosage equivalent in milligrams per day; MMSE, Mini-Mental State Examination; PD-CRS, Parkinson Disease-Cognitive Rating Scale; DASS<sub>21</sub>, Depression Anxiety Stress Scales; PD, Parkinson’s disease; CPs, community dwelling control patients; SD, standard deviation.</p>
</fn>
<fn id="table-fn2-0891988713481267">
<p>
<sup>a </sup>Handedness data were available for 25 patients with PD and 33 CPs.</p>
</fn>
<fn id="table-fn3-0891988713481267">
<p>
<sup>b </sup>
<italic>P </italic>&lt; .01.</p>
</fn>
<fn id="table-fn4-0891988713481267">
<p>
<sup>c </sup>24 patients with PD.</p>
</fn>
<fn id="table-fn5-0891988713481267">
<p>
<sup>d </sup>23 patients with PD.</p>
</fn>
<fn id="table-fn6-0891988713481267">
<p>
<sup>e </sup>13 CPs.</p>
</fn>
<fn id="table-fn7-0891988713481267">
<p>
<sup>f</sup>
<italic>P </italic>&lt; .05<sup>.</sup>
</p>
</fn>
<fn id="table-fn8-0891988713481267">
<p>
<sup>g </sup>7 patients with PD.</p>
</fn>
<fn id="table-fn9-0891988713481267">
<p>
<sup>h </sup>22 CPs.</p>
</fn>
<fn id="table-fn10-0891988713481267">
<p>
<sup>i </sup>
<italic>P </italic>&lt; .001.</p>
</fn>
<fn id="table-fn10a-0891988713481267">
<p>
<sup>j </sup>PD-CRS, Although one patient scored &lt;64, he was judged not to be demented and therefore the PD-CRS may not have been an accurate estimate for him.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Of those patients (n = 25 patients with PD vs n = 33 CPs) who had handedness data available, 3 (12%) of 25 patients with PD were left-handed versus 4 (12.1%) of 25 CPs. There were no statistically significant differences among the 2 groups with respect to handedness. When comparing patients with PD to CPs, the CPs were significantly younger than the patients with PD (<italic>P </italic>&lt; .005), but the CPs were significantly more educated than the patient group (<italic>P </italic>&lt; .006). The CPs also scored significantly higher on the MMSE (<italic>P </italic>&lt; .01) than patients with PD. With respect to the DASS<sub>21</sub>, patients with PD have greater mood impairment. They scored significantly higher on stress (<italic>P </italic>&lt; .04), anxiety (<italic>P </italic>&lt; .0001), depression (<italic>P </italic>&lt; .0001), and overall total score (<italic>P </italic>&lt; .002) than CPs. <xref ref-type="table" rid="table2-0891988713481267">Table 2</xref> presents the background and mood variables for right- versus left-onset patients with PD and CPs.</p>
<table-wrap id="table2-0891988713481267" position="float">
<label>Table 2.</label>
<caption>
<p>Comparison of Demographic, Cognitive, and Mood Data for Right- versus Left-Onset Patients With PD Versus CPs.<sup>a</sup>
</p>
</caption>
<graphic alternate-form-of="table2-0891988713481267" xlink:href="10.1177_0891988713481267-table2.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th>Right-Onset PDs (n = 12); Mean (SD)</th>
<th>Left-Onset PDs (n = 18); Mean (SD)</th>
<th>CPs (n = 35); Mean (SD)</th>
<th>
<italic>P</italic> Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (in years)</td>
<td>67.25 (14.51)</td>
<td>64.89 (10.16)</td>
<td>58.17 (9.78)</td>
<td>.02<sup>b,c,d</sup>
</td>
</tr>
<tr>
<td>Education (in years)</td>
<td>14.50 (2.39)</td>
<td>14.67 (3.35)</td>
<td>16.13 (2.01)</td>
<td>.02<sup>b,e</sup>
</td>
</tr>
<tr>
<td>Gender (n, % female)</td>
<td>1 (8.3%)</td>
<td>5 (27.8%)</td>
<td>18 (51.4%)</td>
<td>.02<sup>b</sup>
</td>
</tr>
<tr>
<td>
<sup>f</sup>Handedness (n, % left-handed)</td>
<td>3 (30%)</td>
<td>2 (15.4%)</td>
<td>4 (12.1%; 2 females)</td>
<td>.01<sup>g</sup>
</td>
</tr>
<tr>
<td>Disease duration (in years)</td>
<td>14.00 (4.69)</td>
<td>10.55 (3.05)</td>
<td>NA</td>
<td>.21</td>
</tr>
<tr>
<td>H-Y Stage</td>
<td>2.92 (0.67)</td>
<td>2.44 (0.51)</td>
<td>NA</td>
<td>.05<sup>b</sup>
</td>
</tr>
<tr>
<td>LDE (mg/d)</td>
<td>570.29<sup>h</sup> (159.40)</td>
<td>597.55<sup>i </sup>(394.69)</td>
<td>NA</td>
<td>.91</td>
</tr>
<tr>
<td>MMSE</td>
<td>27.36<sup>h</sup> (1.49)</td>
<td>28.03<sup>j</sup> (1.32)</td>
<td>28.87<sup>k</sup> (0.82)</td>
<td>.03<sup>b,c,e</sup>
</td>
</tr>
<tr>
<td>
<sup>q</sup>PD-CRS</td>
<td>85.50<sup>l</sup> (21.46)</td>
<td>92.33<sup>m</sup> (6.43)</td>
<td>100.00<sup>n </sup>(12.24)</td>
<td>.39</td>
</tr>
<tr>
<td>DASS<sub>21</sub>–stress</td>
<td>6.42 (4.36)</td>
<td>6.61 (5.30)</td>
<td>3.91 (3.27)</td>
<td>.12</td>
</tr>
<tr>
<td>DASS<sub>21</sub>–anxiety</td>
<td>6.00 (4.26)</td>
<td>5.00 (4.50)</td>
<td>1.89 (2.70)</td>
<td>.0001<sup>e,o,p </sup>
</td>
</tr>
<tr>
<td>DASS<sub>21</sub>–depression</td>
<td>4.92 (3.92)</td>
<td>4.89 (3.79)</td>
<td>2.23 (2.96)</td>
<td>.002<sup>e,g,p</sup>
</td>
</tr>
<tr>
<td>DASS<sub>21</sub>–total</td>
<td>17.33 (10.78)</td>
<td>15.83 (13.21)</td>
<td>8.03 (6.83)</td>
<td>.005<sup>d,g,p</sup>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn11-0891988713481267">
<p>Abbreviations: NA, not applicable; LDE, levodopa dosage equivalent in milligrams per day; MMSE, Mini-Mental State Examination; PD-CRS, Parkinson Disease-Cognitive Rating Scale; DASS<sub>21</sub>, Depression Anxiety Stress Scales; PD, Parkinson disease; CPs, community dwelling control patients; SD, standard deviation.</p>
</fn>
<fn id="table-fn12-0891988713481267">
<p>
<sup>a</sup> The <italic>P</italic> values represent the overall significance level for the 3 groups. Portions of this table were previously published in ref 56.</p>
</fn>
<fn id="table-fn13-0891988713481267">
<p>
<sup>b </sup>
<italic>P </italic>&lt; .05.</p>
</fn>
<fn id="table-fn14-0891988713481267">
<p>
<sup>c</sup> Right-onset PDs versus CPs significantly different at <italic>P </italic>&lt; .05.</p>
</fn>
<fn id="table-fn15-0891988713481267">
<p>
<sup>d </sup>Left-onset PDs vs. CPs significantly different at <italic>P </italic>&lt; .05.</p>
</fn>
<fn id="table-fn16-0891988713481267">
<p>
<sup>e </sup>Left-onset PDs vs. CPs significantly different at <italic>P </italic>&lt; .01.</p>
</fn>
<fn id="table-fn17-0891988713481267">
<p>
<sup>f </sup>Handedness data are available for 25 patients with PD and 33 CPs.</p>
</fn>
<fn id="table-fn18-0891988713481267">
<p>
<sup>g </sup>
<italic>P </italic>&lt; .01.</p>
</fn>
<fn id="table-fn19-0891988713481267">
<p>
<sup>h </sup>8 right-onset PDs.</p>
</fn>
<fn id="table-fn20-0891988713481267">
<p>
<sup>i </sup>16 left-onset PDs.</p>
</fn>
<fn id="table-fn21-0891988713481267">
<p>
<sup>j </sup>15 left-onset PDs.</p>
</fn>
<fn id="table-fn22-0891988713481267">
<p>
<sup>k </sup>13 CPs.</p>
</fn>
<fn id="table-fn23-0891988713481267">
<p>
<sup>l</sup> 4 right-onset PDs.</p>
</fn>
<fn id="table-fn24-0891988713481267">
<p>
<sup>m </sup>3 left-onset PDs.</p>
</fn>
<fn id="table-fn25-0891988713481267">
<p>
<sup>n </sup>22 CPs.</p>
</fn>
<fn id="table-fn26-0891988713481267">
<p>
<sup>o </sup>
<italic>P </italic>&lt; .001.</p>
</fn>
<fn id="table-fn27-0891988713481267">
<p>
<sup>p</sup> right-onset PDs versus CPs significantly different at <italic>P </italic>&lt; .01.</p>
</fn>
<fn id="table-fn26a-0891988713481267">
<p>
<sup>q </sup>Although 1 patient scored &lt;64, he was judged not to be demented and therefore the PD-CRS may not have been an accurate estimate for him.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<sec id="section12-0891988713481267">
<title>Right-Versus Left-Onset Patients with PD-Demographic, Cognitive, and Mood Data</title>
<p>There were no significant differences between the right- and left-onset patient groups in terms of age, education, or LDEs. There were no significant differences among either patient group for the mood variables. Of the 9 patients with right-onset disease, 8 (88.9%) were right-handed and 1 (11.1) was left-handed. Among the 16 patients with left-onset disease, 14 (87.5%) were right-handed and 2 (12.5%) were left-handed. The difference among the 2 patient groups and handedness were not statistically significant.</p>
</sec>
<sec id="section13-0891988713481267">
<title>Right-Onset Patients with PD Versus CPs - Demographic, Cognitive, and Mood Data</title>
<p>When comparing right-onset patients with PD with CPs, the right-onset patient group was significantly older than CPs (<italic>P </italic>&lt; .04). The CPs scored significantly higher on the MMSE than the right-onset patients with PD (<italic>P </italic>&lt; .02). The right-onset patient group was also significantly more anxious (<italic>P </italic>&lt; .0001), depressed (<italic>P </italic>&lt; .005), and had higher DASS<sub>21</sub> total scores (<italic>P </italic>&lt; .002) than CPs.</p>
</sec>
<sec id="section14-0891988713481267">
<title>Left-Onset Patients with PD Versus CPs - Demographic, Cognitive, and Mood Data</title>
<p>The CPs scored significantly higher on the MMSE (<italic>P </italic>&lt; .01) and were more educated (<italic>P </italic>&lt; .01) than left-onset patients with PD. The left-onset patient group was significantly older than CPs (<italic>P </italic>&lt; .02), more anxious (<italic>P </italic>&lt; .001), depressed (<italic>P </italic>&lt; .003), and had higher DASS<sub>21</sub> total scores (<italic>P </italic>&lt; .04). <xref ref-type="table" rid="table3-0891988713481267">Table 3</xref> represents the medication profile of both the patient groups. <xref ref-type="table" rid="table4-0891988713481267">Table 4</xref> presents the Stroop Color–Word Interference Test findings.</p>
<table-wrap id="table3-0891988713481267" position="float">
<label>Table 3.</label>
<caption>
<p>Medication Profile of Right- Versus Left-Onset Patients With PD.<sup>a</sup>
</p>
</caption>
<graphic alternate-form-of="table3-0891988713481267" xlink:href="10.1177_0891988713481267-table3.tif"/>
<table>
<thead>
<tr>
<th>
<bold> </bold>
</th>
<th>Right-Onset PDs (n = 8), % (n)</th>
<th>Left-Onset PDs (n = 16), % (n)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Levodopa</td>
<td>87.5% (7)</td>
<td>87.5% (14)</td>
</tr>
<tr>
<td>Dopamine Agonists</td>
<td>75.0% (6)</td>
<td>68.8% (11)</td>
</tr>
<tr>
<td>Anticholinergic</td>
<td>0% (0)</td>
<td>18.8% (3)</td>
</tr>
<tr>
<td>COMT inhibitor</td>
<td>37.5% (3)</td>
<td>25.0% (4)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn29-0891988713481267">
<p>Abbreviation: PD, Parkinson disease; COMT, catechol-<italic>O</italic>-methyltransferase.</p>
</fn>
<fn id="table-fn30-0891988713481267">
<p>
<sup>a</sup> Medication information was unavailable for 4 right-onset and 2 left-onset patients with PD (all males). Sample sizes: For right-onset PDs,1 (12.5%) female and for left-onset PDs, 5 females (31.3%). This table was previously published in ref 56.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table4-0891988713481267" position="float">
<label>Table 4.</label>
<caption>
<p>Mean Number of Words Read for the Stroop Color–Word Interference Test for Right- Versus Left-Onset Patients With PD Versus CPs.<sup>a</sup>
</p>
</caption>
<graphic alternate-form-of="table4-0891988713481267" xlink:href="10.1177_0891988713481267-table4.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th>Right-Onset PDs (n = 8), Mean (SD)</th>
<th>Left-Onset PDs (n = 16), Mean (SD)</th>
<th>CPs (n = 13), Mean (SD)</th>
<th>
<italic>P</italic> Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Word</td>
<td>74.63 (24.26)</td>
<td>81.50 (10.82)</td>
<td>96.23 (18.31)</td>
<td>.02<sup>b,c</sup>
</td>
</tr>
<tr>
<td>Color</td>
<td>48.25 (20.56)</td>
<td>55.63 (9.91)</td>
<td>68.46 (11.14)</td>
<td>.004<sup>d,e</sup>
</td>
</tr>
<tr>
<td>Color-word</td>
<td>25.63 (13.14)</td>
<td>33.25 (5.79)</td>
<td>36.54 (9.79)</td>
<td>.04<sup>b,c</sup>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn31-0891988713481267">
<p>Abbreviation: PD, Parkinson disease; CPs, community dwelling control patients; SD, standard deviation.</p>
</fn>
<fn id="table-fn32-0891988713481267">
<p>
<sup>a</sup> <italic>P</italic> values represent the overall significance level for the 3 groups. The raw scores are reported. Sample sizes: For right-onset right-onset PDs, 1 (12.5%) female; for left-onset PDs, 5 (31.3%) females; for CPs, 8 (61.5%) females. This table was previously published in ref 56.</p>
</fn>
<fn id="table-fn33-0891988713481267">
<p>
<sup>b </sup>
<italic>P </italic>&lt; .05.</p>
</fn>
<fn id="table-fn34-0891988713481267">
<p>
<sup>c </sup>Right-onset PDs and CPs significantly different at <italic>P </italic>&lt; .05<sub>.</sub>
</p>
</fn>
<fn id="table-fn35-0891988713481267">
<p>
<sup>d </sup>
<italic>P </italic>&lt; .01.</p>
</fn>
<fn id="table-fn36-0891988713481267">
<p>
<sup>e</sup> Right-onset PDs and CPs significantly different at <italic>P </italic>&lt; .01. </p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section15-0891988713481267">
<title>Stroop Color–Word Interference Test</title>
<p>For all 3 test conditions, the right-onset patients with PD performed worse than the CPs but not significantly worse than the left-onset patients with PD. The <italic>F </italic>tests for the word reading, color naming, and inhibition test cards are presented, respectively: <italic>F</italic>(2,34) = 4.62, <italic>P </italic>&lt; .02; <italic>F</italic>(2,34) = 6.50, <italic>P </italic>&lt; .004; <italic>F</italic>(2,34) = 3.55, <italic>P </italic>&lt; .04. There was a trend for the left-onset patient group to perform better than the right-onset patient group on the inhibition test card, <italic>t</italic>(22) = −1.92, <italic>P </italic>&lt; .07.</p>
</sec>
<sec id="section15a-0891988713481267">
<title>Response on Apathy Evaluation Scale</title>
<p>
<xref ref-type="table" rid="table5-0891988713481267">Table 5</xref> presents the responses of the apathy measures. When looking only at AES total scores on the self version with a clinical cutoff score of ≥38, 23.3% (7 of 30) patients with PD and 20.0% (7 of 35) of CPs exhibited clinically significant levels of apathy. Of the patients with right-onset PD, 41.7% (5 of 12) had clinically significant levels of apathy versus 11.1% (2 of 18) of the patients with left-onset PD. A chi-square (χ<sup>2</sup>) test was used to determine whether there was a significant difference between the proportions of patients with right- and left-onset PD who were clinically apathetic. This difference was statistically significant, χ<sup>2</sup> (1) = 30.00, <italic>P</italic> &lt; .0001.</p>
<table-wrap id="table5-0891988713481267" position="float">
<label>Table 5.</label>
<caption>
<p>The AES Scores for Right- Versus Left-Onset Patients With PD Versus CPs.<sup>a,b</sup>
</p>
</caption>
<graphic alternate-form-of="table5-0891988713481267" xlink:href="10.1177_0891988713481267-table5.tif"/>
<table>
<thead>
<tr>
<th> </th>
<th>Right-Onset PDs (n = 12); Mean (SD)</th>
<th>Left-Onset PDs (n = 18); Mean (SD)</th>
<th>CPs (n = 35); Mean (SD)</th>
<th>
<italic>P</italic> Value</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="5">AES: self version</td>
</tr>
<tr>
<td>Cognitive</td>
<td>16.08 (3.83)</td>
<td>13.39 (3.38)</td>
<td>12.83 (3.43)</td>
<td>.04<sup>c,d</sup>
</td>
</tr>
<tr>
<td>Behavioral</td>
<td>10.58 (3.03)</td>
<td>7.67 (2.03)</td>
<td>7.71 (2.55)</td>
<td>.01<sup>d,e,f</sup>
</td>
</tr>
<tr>
<td>Emotional</td>
<td>4.33 (1.56)</td>
<td>3.89 (1.18)</td>
<td>3.77 (1.26)</td>
<td>.54</td>
</tr>
<tr>
<td>Other</td>
<td>6.58 (1.93)</td>
<td>5.11 (1.57)</td>
<td>5.03 (1.67)</td>
<td>.04<sup>c,d,g</sup>
</td>
</tr>
<tr>
<td>Total</td>
<td>37.58 (9.15)</td>
<td>30.06 (7.30)</td>
<td>29.34 (7.59)</td>
<td>.03<sup>c,d,g</sup>
</td>
</tr>
<tr>
<td colspan="5">AES: informant version </td>
</tr>
<tr>
<td>Cognitive</td>
<td>14.58 (5.66)</td>
<td>13.50 (3.84)</td>
<td>12.23 (3.41)</td>
<td>.34</td>
</tr>
<tr>
<td>Behavioral</td>
<td>9.25 (3.31)</td>
<td>8.00 (2.09)</td>
<td>7.17 (2.05)</td>
<td>.10</td>
</tr>
<tr>
<td>Emotional</td>
<td>4.25 (2.26)</td>
<td>3.39 (1.24)</td>
<td>3.40 (1.19)</td>
<td>.73</td>
</tr>
<tr>
<td>Other</td>
<td>6.25 (2.30)</td>
<td>4.39 (1.46)</td>
<td>4.63 (1.85)</td>
<td>.05<sup>c,d,g</sup>
</td>
</tr>
<tr>
<td>Total</td>
<td>34.33 (12.81)</td>
<td>29.28 (7.42)</td>
<td>27.43 (7.67)</td>
<td>.20</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn37-0891988713481267">
<p>Abbreviation: PD, Parkinson disease; CPs, community dwelling control patients; SD, standard deviation; AES, Apathy Evaluation Scale.</p>
</fn>
<fn id="table-fn38-0891988713481267">
<p>
<sup>a </sup>
<italic>P</italic> values represent the overall significance level for the 3 groups. For right-onset PDs, 1 (8.3%) female; for left-onset PDs, 5 (27.8%) females; for CPs, 18 (51.4%) females.</p>
</fn>
<fn id="table-fn39-0891988713481267">
<p>
<sup>b</sup> Apathy Evaluation Scale minimum (maximum) scores for each domain: cognitive = 8 (32); behavioral = 5 (20); emotional = 2 (8); other = 3 (12); maximum total = 72; minimum total = 18; higher scores indicate greater apathy. This table was previously published in ref 56.</p>
</fn>
<fn id="table-fn40-0891988713481267">
<p>
<sup>c </sup>
<italic>P</italic>&lt;.05.</p>
</fn>
<fn id="table-fn41-0891988713481267">
<p>
<sup>d</sup> right-onset PDs and CPs significantly different at <italic>P</italic>&lt;.01.</p>
</fn>
<fn id="table-fn42-0891988713481267">
<p>
<sup>e </sup>
<italic>P</italic>&lt;.01.</p>
</fn>
<fn id="table-fn43-0891988713481267">
<p>
<sup>f </sup>right-onset and left-onset PDs significantly different at <italic>P</italic>&lt;.01.</p>
</fn>
<fn id="table-fn44-0891988713481267">
<p>
<sup>g </sup>right-onset and left-onset PDs significantly different at <italic>P</italic>&lt;.05. </p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section16-0891988713481267">
<title>Right-Versus Left-Onset Patients with PD - AES Data</title>
<p>When comparing only self responses on the AES, right-onset patients with PD had significantly higher total apathy scores (<italic>P </italic>&lt; .03). Right-onset patients with PD also scored significantly higher than left-onset patients with PD on the following apathy domains: behavioral (<italic>P </italic>&lt; .008) and “other” (<italic>P </italic>&lt; .03). Right-onset patients with PD were less likely to be aware of their levels of apathy, as indicated by the “other” domain score.</p>
</sec>
<sec id="section17-0891988713481267">
<title>Right-Onset Patients With PD Versus CPs - AES Data</title>
<p>Right-onset patients with PD had significantly higher levels of apathy than CPs (total score, <italic>P </italic>&lt; .009). They also scored significantly higher than CPs in the following apathy self domains: cognitive (<italic>P </italic>&lt; .01), behavioral (<italic>P </italic>&lt; .005), and “other” (<italic>P </italic>&lt; .02).</p>
</sec>
<sec id="section18-0891988713481267">
<title>Left-Onset Patients With PD Versus CPs-AES Data</title>
<p>There were no significant differences for any self or informant apathy total scores or domain scores between left-onset patients with PD and CPs.</p>
</sec>
<sec id="section19a-0891988713481267">
<title>Depression and Apathy among Patients with PD</title>
<p>Patients with PD were divided into the following groups: depressed only, apathetic only, apathetic + depression, and neither (see <xref ref-type="table" rid="table6-0891988713481267">Table 6</xref>).</p>
<table-wrap id="table6-0891988713481267" position="float">
<label>Table 6.</label>
<caption>
<p>Comparison of Depression and Apathy Among Patients With PD (n = 30).<sup>a</sup>
</p>
</caption>
<graphic alternate-form-of="table6-0891988713481267" xlink:href="10.1177_0891988713481267-table6.tif"/>
<table>
<thead>
<tr>
<th>% Apathy Only (n = 3; 2 RO, 1 LO)</th>
<th>% Apathy + Depression (n = 4; 3 RO, 1 LO)</th>
<th>% Depression Only (n = 9; 2 RO, 7 LO)</th>
<th>% Neither (n = 14; 5 RO, 9 LO)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.0% (3/30)</td>
<td>13.3% (4/30)</td>
<td>30.0% (9/30) </td>
<td>46.7% (14/30) </td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn45-0891988713481267">
<p>Abbreviations: PD, Parkinson disease; RO, right-onset disease; LO, left-onset disease.</p>
</fn>
<fn id="table-fn46-0891988713481267">
<p>
<sup>a </sup>For apathy + depression, 1 (25%) female; for depression only, 2 (22.2%) females; for neither, 3 (21.4%) females.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section19-0891988713481267">
<title>Predictors of Apathy</title>
<p>Adjusted ORs (AORs) were calculated to examine the relationship between patients having right- onset PD and left-onset PD and developing a certain type of apathy. Patients with right-onset disease had greater odds of developing all types of apathy except behavioral apathy than patients with left-onset disease. The AORs were the following: cognitive apathy: AOR = 6.96, confidence interval (CI) = 1.059-45.716; behavioral apathy: AOR = 6.63, CI = 1.029-42.751; emotional apathy: AOR = 2.76, CI = 0.504-15.139; other apathy: AOR = 10.42, CI = 1.282-84.665.</p>
</sec>
<sec id="section20-0891988713481267">
<title>Predictors of AES Total Score</title>
<p>These analyses examined the relationship between side of onset, disease severity (H-Y stage), gender, and DASS<sub>21</sub> total score on the self total AES score. The overall model was significant (<italic>P </italic>= .01) accounting for 38.4% of the variance in total AES score. When each variable was examined, the DASS<sub>21</sub> total score was the only significant predictor of total AES score in patients with PD (β = .334, <italic>P</italic> = .048). Hierarchical logistic regression was conducted for AES total score as well as the OR.</p>
</sec>
<sec id="section21-0891988713481267">
<title>Correlations for Right-Onset Patients With PD</title>
<p>Patients with right-onset PD who were older scored significantly lower on the MMSE, ρ = −.83, <italic>P </italic>&lt; .01. Higher scores on the MMSE correlated strongly with lower scores on the emotional domain of apathy, ρ = −.82, <italic>P </italic>&lt; .01. Greater anxiety scores correlated with higher cognitive domain scores, ρ = .87, <italic>P </italic>&lt; .0001, behavioral domain scores, ρ = .68, <italic>P </italic>&lt; .02, higher “other” domain scores, ρ = .73, <italic>P </italic>&lt; .007, and higher total apathy scores, ρ = .86, <italic>P </italic>&lt; .0001. Higher DASS<sub>21</sub> total scores correlated with higher scores within the cognitive domain of apathy, ρ = .74, <italic>P </italic>&lt; .006, and the “other” domain, ρ = .77, <italic>P </italic>&lt; .004.</p>
</sec>
<sec id="section22-0891988713481267">
<title>Correlations for Left-Onset Patients With PD</title>
<p>There were no correlations among any of the background or mood variables and the AES total score or domain scores for left-onset patients with PD.</p>
</sec>
<sec id="section23-0891988713481267">
<title>Patient Versus Informant Scores on the AES</title>
<p>A Wilcoxon Signed Rank Test was performed in paired samples to examine self versus informant scores for all AES domains and total scores. There were no differences in scores for self versus informant scores for right-onset patients with PD. There was a trend for left-onset patients’ informants to rank the patients lower on the “other” domain, indicating that the patients had a more accurate understanding of their problems, had initiative, and were more motivated (<italic>P </italic>= .05) than patients themselves indicated. For CPs, there was a significant difference between self and informant ratings for the emotional domain. This meant that informants of CPs ranked CPs as having less emotional apathy than CPs had ranked themselves (<italic>P </italic>&lt; .03) and as having less “other” apathy (<italic>P </italic>&lt; .0001), meaning they were aware of their levels of motivation. There were no other significant differences in any of the apathy domains among the groups.</p>
</sec>
</sec>
<sec id="section24-0891988713481267">
<title>Discussion</title>
<p>This study corroborates the findings from the Cubo et al<sup><xref ref-type="bibr" rid="bibr10-0891988713481267">10</xref></sup> study and adds to the existing literature by documenting side of onset effects on apathy severity differences in patients with PD. Previous studies reporting on apathy seem to include only early-stage patients with PD.<sup><xref ref-type="bibr" rid="bibr10-0891988713481267">10</xref></sup>
<sup>,</sup>
<sup><xref ref-type="bibr" rid="bibr30-0891988713481267">30</xref></sup> Earlier studies of apathy in patients with PD (see Supplementary Table 1; A Summary of Previous Research Examining Apathy in Patients With Parkinson Disease is available at http://jgp.sagepub.com/supplemental) did not report side of onset effects and used other measures besides the AES to assess incidence and clinical presentation including the Apathy Scale<sup><xref ref-type="bibr" rid="bibr8-0891988713481267">8</xref></sup>
<sup>,</sup>
<sup><xref ref-type="bibr" rid="bibr31-0891988713481267">31</xref><xref ref-type="bibr" rid="bibr32-0891988713481267"/>–<xref ref-type="bibr" rid="bibr33-0891988713481267">33</xref></sup>; the Neuropsychiatric Inventory<sup><xref ref-type="bibr" rid="bibr5-0891988713481267">5</xref></sup>
<sup>,</sup>
<sup><xref ref-type="bibr" rid="bibr12-0891988713481267">12</xref></sup>
<sup>,</sup>
<sup><xref ref-type="bibr" rid="bibr34-0891988713481267">34</xref><xref ref-type="bibr" rid="bibr35-0891988713481267"/><xref ref-type="bibr" rid="bibr36-0891988713481267"/>–<xref ref-type="bibr" rid="bibr37-0891988713481267">37</xref></sup>; the Lille Apathy Rating Scale<sup><xref ref-type="bibr" rid="bibr12-0891988713481267">12</xref></sup>
<sup>,</sup>
<sup><xref ref-type="bibr" rid="bibr38-0891988713481267">38</xref><xref ref-type="bibr" rid="bibr39-0891988713481267"/>–<xref ref-type="bibr" rid="bibr40-0891988713481267">40</xref></sup>; the Apathy Inventory <sup><xref ref-type="bibr" rid="bibr41-0891988713481267">41</xref></sup>; and clinical interview techniques. <sup><xref ref-type="bibr" rid="bibr42-0891988713481267">42</xref></sup>
</p>
<p>To begin to understand the findings in this study relative to asymmetry in PD, we need to first address the neuroanatomy/neurophysiology of apathy. Levy and Czernecki<sup><xref ref-type="bibr" rid="bibr43-0891988713481267">43</xref></sup> suggest that apathy in PD can result from several types of dysfunctions including lesions to the main dopaminergic pathways (mesocorticolimbic and nigrostriatal). Other nondopaminergic pathways that can be affected include the cholinergic pathway, noradrenergic, and serotoninergic ascending pathways as well as direct cortical lesions in associative cortices. Some research has even found that olfaction impairment may be indicative of greater apathy.<sup><xref ref-type="bibr" rid="bibr44-0891988713481267">44</xref></sup> The mesocorticolimbic tract that projects to the frontal lobes is less affected early in PD than the nigrostriatal tract.<sup><xref ref-type="bibr" rid="bibr45-0891988713481267">45</xref></sup> Furthermore, neuroimaging studies of patients with PD and apathy reveal that laterality differences do exist. For instance, Reijnders et al<sup><xref ref-type="bibr" rid="bibr12-0891988713481267">12</xref></sup> report low gray matter density in the right posterior cingulate gyrus and the right precuneus. As Reijnders et al<sup><xref ref-type="bibr" rid="bibr12-0891988713481267">12</xref></sup> speculate, the loss of gray matter in the prefrontal cortex could be related to less initiative and motivation to initiate movements in apathetic patients with PD.</p>
<sec id="section25-0891988713481267">
<title>Asymmetric Profile of Apathy in PD</title>
<p>Why do the right-onset patients with PD display greater levels of apathy? Let us first review what reasons do not account for this asymmetric profile of apathy in patients with PD from our study. We found the right-onset patient group to be slightly older and more educated than the left-onset patient group, but these differences were not statistically significant. Right-onset patients with PD also had greater disease stage on average than left-onset patients with PD, but when examining medication dosages across the groups, there were no significant differences. Greater apathy in right-onset patients with PD also cannot be attributed to greater mood dysfunction, because there were no significant differences between the patient groups on the mood variables (see <xref ref-type="table" rid="table2-0891988713481267">Table 2</xref>). Apathy previously has not been found to be related to depression, disease duration, or motor symptom severity.<sup><xref ref-type="bibr" rid="bibr46-0891988713481267">46</xref></sup>
</p>
<p>Motor symptoms of PD are not displayed until there is approximately an 80% loss of striatal dopamine and a 50% loss of nigral neurons, with the loss more predominant on one side. <sup><xref ref-type="bibr" rid="bibr45-0891988713481267">45</xref></sup>
<sup>,</sup>
<sup><xref ref-type="bibr" rid="bibr47-0891988713481267">47</xref></sup> The striatum, particularly the dorsal portion, is the main input region of the entire basal ganglia.<sup><xref ref-type="bibr" rid="bibr48-0891988713481267">48</xref></sup> It has been found that even healthy brains evidence less dopamine in the right striatum, thus suggesting that the left hemisphere is more susceptible to greater dopaminergic loss than the right hemisphere.<sup><xref ref-type="bibr" rid="bibr49-0891988713481267">49</xref></sup> This side of onset effect has also been verified by independent pathology studies <sup><xref ref-type="bibr" rid="bibr45-0891988713481267">45</xref></sup>
<sup>,</sup>
<sup><xref ref-type="bibr" rid="bibr50-0891988713481267">50</xref></sup> and neuroimaging studies.<sup><xref ref-type="bibr" rid="bibr51-0891988713481267">51</xref><xref ref-type="bibr" rid="bibr52-0891988713481267"/><xref ref-type="bibr" rid="bibr53-0891988713481267"/><xref ref-type="bibr" rid="bibr54-0891988713481267"/>–<xref ref-type="bibr" rid="bibr55-0891988713481267">55</xref></sup>
</p>
</sec>
<sec id="section26-0891988713481267">
<title>Types of Apathy</title>
<p>Levy and Dubois<sup><xref ref-type="bibr" rid="bibr3-0891988713481267">3</xref></sup> categorize apathy into the following 3 specific types: emotional-affective, cognitive-affective, and auto-activation deficit. Learning how each of these apathy profiles are expressed in patients with PD can help elucidate the underpinnings of apathy and also side of onset effects resulting from apathy.<sup><xref ref-type="bibr" rid="bibr7-0891988713481267">7</xref></sup> We believe the patients in this study evidenced the cognitive-affective type of apathy based on the following conclusions. First, patients with right-onset disease, in particular, showed the highest levels of cognitive apathy on the AES. Cognitive apathy is described as a reduction in the number of expressions of intentions to perform a goal-directed behavior. This form of apathy is most commonly associated with tests measuring executive cognitive function (ECF) such as the Stroop Color–Word Interference Test, the Tower of London (TOL) task, and the Wisconsin Card Sorting Task (WCST).<sup><xref ref-type="bibr" rid="bibr3-0891988713481267">3</xref></sup> All of these ECF tests require the patient to set future goals, to plan how to implement these goals, and then be able to implement the activities to achieve the goals while simultaneously exhibiting cognitive flexibility. In this study, the right-onset patient group performed worse on the Stroop Color–Word Interference Test than left-onset patients with PD. Second, those patients with PD who would exhibit this type of apathy are not going to express intentions to work toward a future goal, are going to have greater difficulty in completing the TOL task, will do poorly on the Stroop Color–Word Interference Test and the WCST, and will be unable to adjust their behavior to coincide with achieving their overarching goal. There is a general reduction in overt behavior on behalf of the patient to form any beliefs or desires to work towards future goal-directed actions. Finally, the emotional subscale of the AES was the lowest type of apathy found in either patient group. This type of apathy, as mentioned previously, seems to present more in the early stages of the disease.</p>
</sec>
<sec id="section27-0891988713481267">
<title>The Relationship of Apathy to Dementia</title>
<p>Previous research<sup><xref ref-type="bibr" rid="bibr36-0891988713481267">36</xref></sup> indicates that apathy may be part of the expected course of PD and related to dopaminergic circuits, but the dementia component may be related to non-dopaminergic pathways. In addition, apathetic patients with PD have been found to perform poorly on neuropsychological and ECF tests at initial study enrollment and have increased dementia at follow-up.<sup><xref ref-type="bibr" rid="bibr39-0891988713481267">39</xref></sup>
</p>
</sec>
</sec>
<sec id="section28-0891988713481267">
<title>Conclusion</title>
<p>In summary, this increased apathy, specifically among patients with right-onset disease, is likely related to an inability to effectively activate cognitive processes that access action representations of agency.<sup><xref ref-type="bibr" rid="bibr56-0891988713481267">56</xref></sup> Agency is the part of the self that sets goals, makes decisions for the self, generates or is the cause of an action, and monitors and corrects errors in ongoing actions.<sup><xref ref-type="bibr" rid="bibr57-0891988713481267">57</xref><xref ref-type="bibr" rid="bibr58-0891988713481267"/><xref ref-type="bibr" rid="bibr59-0891988713481267"/><xref ref-type="bibr" rid="bibr60-0891988713481267"/><xref ref-type="bibr" rid="bibr61-0891988713481267"/><xref ref-type="bibr" rid="bibr62-0891988713481267"/><xref ref-type="bibr" rid="bibr63-0891988713481267"/><xref ref-type="bibr" rid="bibr64-0891988713481267"/><xref ref-type="bibr" rid="bibr65-0891988713481267"/><xref ref-type="bibr" rid="bibr66-0891988713481267"/>–<xref ref-type="bibr" rid="bibr67-0891988713481267">67</xref></sup> This is the exact function of the basal ganglia, frontal lobes, and frontal basal ganglia systems. If patients cannot efficiently recruit action schemas that normally help the individual to initiate and to control ongoing actions,<sup><xref ref-type="bibr" rid="bibr68-0891988713481267">68</xref></sup> then loss of access to these action schemas should result in an overall reduction in overt behaviors, which is exactly what we see, especially among patients with PD who are thought to have cognitive-affective apathy in this sample.</p>
<sec id="section29-0891988713481267">
<title>Future Research</title>
<p>As has already been demonstrated, the neuropathology and neurophysiology of apathy is quite complex and is further complicated by side of onset effects. What is unclear is which subtype of apathy contributes to predicting dementia. It is our supposition that patients with right-onset PD will be at greater risk of developing dementia. Although some progress is being made elucidating these various types of apathy based on neuropathophysiology, additional questions remain unanswered. Could apathy in patients with PD progress over time from emotional apathy to cognitive apathy to finally auto-activation deficit? Is it possible for a patient with PD to have auto-activation deficit? Suggestions for future research include conducting more studies to understand how apathy manifests in mid to late stages of PD in addition to elucidating better treatment strategies.</p>
</sec>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="other" id="fn1-0891988713481267">
<label>Authors’ Contributions</label>
<p>EH initiated the study, designed data collection tools, monitored data collection for the entire study, wrote the statistical analysis plan, cleaned and analyzed the data, and drafted and revised the article. She is the guarantor. PM and RD assisted with data interpretation, drafting, and revising the manuscript.</p></fn>
<fn fn-type="other" id="fn2-0891988713481267">
<label>Authors’ Note</label>
<p>Both the Boston University Medical Center (BUMC) and Boston Veterans Affairs Medical Center (VAMC) institutional review boards approved this study. Some material contained within this manuscript was previously published in Harris, E. <italic>Neurocognition and self-regulation of the agentic self in patients with Parkinson’s disease</italic> (Doctoral dissertation). Boston University, Boston, MA; 2011. Dr Harris owns the copyright to this material. This study is based upon work supported, in part, by the Office of Research and Development, Medical Research Service, Department of Veterans Affairs.</p></fn>
<fn fn-type="conflict" id="fn3-0891988713481267">
<label>Declaration of Conflicting Interests</label>
<p>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn4-0891988713481267">
<label>Funding</label>
<p>The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the National Institute on Deafness and Other Communication Disorders. Competing Interests. There are no competing interests among any of the authors, financial or otherwise.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0891988713481267">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marin</surname>
<given-names>RS</given-names>
</name>
</person-group>. <article-title>Apathy: concept, syndrome, neural mechanisms, and treatment</article-title>. <source>Semin Clin Neuropsychiatry</source>. <year>1996</year>;<volume>1</volume>(<issue>4</issue>):<fpage>304</fpage>–<lpage>314</lpage>.</citation>
</ref>
<ref id="bibr2-0891988713481267">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Levy</surname>
<given-names>R</given-names>
</name>
</person-group>. <article-title>Apathy: a pathology of goal-directed behavior: a new concept of the clinic and pathophysiology of apathy</article-title>. <source>Rev Neurol (Paris)</source>. <year>2012</year>;<volume>168</volume>(<issue>8-9</issue>):<fpage>585</fpage>–<lpage>597</lpage>.</citation>
</ref>
<ref id="bibr3-0891988713481267">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Levy</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Dubois</surname>
<given-names>B</given-names>
</name>
</person-group>. <article-title>Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits</article-title>. <source>Cereb Cortex</source>. <year>2006</year>;<volume>16</volume>(<issue>7</issue>):<fpage>916</fpage>–<lpage>928</lpage>.</citation>
</ref>
<ref id="bibr4-0891988713481267">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Benoit</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Robert</surname>
<given-names>PH</given-names>
</name>
</person-group>. <article-title>Imaging correlates of apathy and depression in Parkinson’s disease</article-title>. <source>J Neurol Sci</source>. <year>2011</year>;<volume>310</volume>(<issue>1-2</issue>):<fpage>58</fpage>–<lpage>60</lpage>.</citation>
</ref>
<ref id="bibr5-0891988713481267">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Levy</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Cummings</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Fairbanks</surname>
<given-names>LA</given-names>
</name>
<etal/>
</person-group> <article-title>Apathy is not depression</article-title>. <source>J Neuropsychiatry Clin Neurosci</source>. <year>1998</year>;<volume>10</volume>(<issue>3</issue>):<fpage>314</fpage>–<lpage>319</lpage>.</citation>
</ref>
<ref id="bibr6-0891988713481267">
<label>6</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Durso</surname>
<given-names>R</given-names>
</name>
</person-group>. <article-title>Dementia in Parkinson disease</article-title>. In: <person-group person-group-type="editor">
<name>
<surname>McNamara</surname>
<given-names>P</given-names>
</name>
</person-group>, ed. <source>Dementia: Volume 2: Science and Biology</source>. <publisher-loc>Santa Barbara, CA</publisher-loc>: <publisher-name>Praeger Publishers</publisher-name>; <year>2011</year>:<fpage>159</fpage>–<lpage>182</lpage>.</citation>
</ref>
<ref id="bibr7-0891988713481267">
<label>7</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Harris</surname>
<given-names>E</given-names>
</name>
</person-group>. <article-title>Relation of apathy to dementia in patients with Parkinson’s disease</article-title>. In: <person-group person-group-type="editor">
<name>
<surname>McNamara</surname>
<given-names>P</given-names>
</name>
</person-group>, ed. <source>Dementia: Volume 2: Science and Biology</source>. <publisher-loc>Santa Barbara, CA</publisher-loc>: <publisher-name>Praeger Publishers</publisher-name>; <year>2011</year>:<fpage>221</fpage>–<lpage>236</lpage>.</citation>
</ref>
<ref id="bibr8-0891988713481267">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Starkstein</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Mayberg</surname>
<given-names>HS</given-names>
</name>
<name>
<surname>Leiguarda</surname>
<given-names>R</given-names>
</name>
</person-group>, et al. <article-title>A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with Parkinson's disease</article-title>. <source>J Neurol Neurosurg Psychiatry</source>. <year>1992</year>;<volume>55</volume>(<issue>5</issue>):<fpage>377</fpage>–<lpage>382</lpage>.</citation>
</ref>
<ref id="bibr9-0891988713481267">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kirsch-Darrow</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Fernandez</surname>
<given-names>HF</given-names>
</name>
<name>
<surname>Marsiske</surname>
<given-names>M</given-names>
</name>
</person-group>, et al. <article-title>Dissociating apathy and depression in Parkinson disease</article-title>. <source>Neurol</source>. <year>2006</year>;<volume>67</volume>(<issue>1</issue>):<fpage>33</fpage>–<lpage>38</lpage>.</citation>
</ref>
<ref id="bibr10-0891988713481267">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cubo</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Benito-Leon</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Coronell</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Armesto</surname>
<given-names>D</given-names>
</name>
</person-group>. <article-title>Clinical correlates of apathy in patients recently diagnosed with Parkinson’s disease: the ANIMO study</article-title>. <source>Neuroepidemiology</source>. <year>2012</year>;<volume>38</volume>(<issue>1</issue>):<fpage>48</fpage>–<lpage>55</lpage>.</citation>
</ref>
<ref id="bibr11-0891988713481267">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kostic</surname>
<given-names>VS</given-names>
</name>
<name>
<surname>Filippi</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Neuroanatomical correlates of depression and apathy in Parkinson’s disease: magnetic resonance imaging studies</article-title>. <source>J Neurol Sci</source>. <year>2011</year>;<volume>310</volume>(<issue>1-2</issue>):<fpage>61</fpage>–<lpage>63</lpage>.</citation>
</ref>
<ref id="bibr12-0891988713481267">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reijnders</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Scholtissen</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Weber</surname>
<given-names>WE</given-names>
</name>
</person-group>, et al. <article-title>Neuroanatomical correlates of apathy in Parkinson’s disease: a magnetic resonance imaging study using voxel-based morphometry</article-title>. <source>Mov Disord</source>. <year>2010</year>;<volume>25</volume>(<issue>14</issue>):<fpage>2318</fpage>–<lpage>2325</lpage>.</citation>
</ref>
<ref id="bibr13-0891988713481267">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hughes</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Daniel</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Kilford</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Lees</surname>
<given-names>AJ</given-names>
</name>
</person-group>. <article-title>Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinic-pathological study of 100 cases</article-title>. <source>J Neurol Neurosurg Psychiatr</source>. <year>1992</year>;<volume>55</volume>(<issue>3</issue>):<fpage>181</fpage>–<lpage>184</lpage>.</citation>
</ref>
<ref id="bibr14-0891988713481267">
<label>14</label>
<citation citation-type="book">
<collab collab-type="author">American Psychiatric Association (APA)</collab>. <source>Diagnostic and Statistical Manual for Mental Disorders, Text Revision</source>. <edition>4th ed.</edition> <publisher-loc>Washington, DC</publisher-loc>: <publisher-name>American Psychiatric Association</publisher-name>; <year>2000</year>.</citation>
</ref>
<ref id="bibr15-0891988713481267">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jimenez-Shahed</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Davidson</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Jankovic</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>The role of dopaminergic medication doses in impulse control disorders in Parkinson’s disease</article-title>. <source>Mov Disord</source>. <year>2008</year>;<volume>23</volume>(<issue>suppl 1</issue>):<fpage>S82</fpage>.</citation>
</ref>
<ref id="bibr16-0891988713481267">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Uitti</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Baba</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Whaley</surname>
<given-names>NR</given-names>
</name>
</person-group>, et al. <article-title>Parkinson’s disease: handedness predicts asymmetry</article-title>. <source>Neurol</source>. <year>2005</year>;<volume>64</volume>(<issue>11</issue>):<fpage>1925</fpage>–<lpage>1930</lpage>.</citation>
</ref>
<ref id="bibr17-0891988713481267">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goetz</surname>
<given-names>CG</given-names>
</name>
<name>
<surname>Tilley</surname>
<given-names>BC</given-names>
</name>
<name>
<surname>Shaftman</surname>
<given-names>SR</given-names>
</name>
<etal/>
</person-group> <article-title>Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results</article-title>. <source>Mov Disord</source>. <year>2008</year>;<volume>23</volume>(<issue>15</issue>):<fpage>2129</fpage>–<lpage>2170</lpage>.</citation>
</ref>
<ref id="bibr18-0891988713481267">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Folstein</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Folstein</surname>
<given-names>S</given-names>
</name>
<name><surname>McHugh</surname><given-names>P</given-names></name>
</person-group>. <article-title>“Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician</article-title>. <source>J Psychiatr Res</source>. <year>1975</year>;<volume>12</volume>(<issue>3</issue>):<fpage>189</fpage>–<lpage>198</lpage>.</citation>
</ref>
<ref id="bibr19-0891988713481267">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pagonabarraga</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kulisevsky</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Llebaria</surname>
<given-names>G</given-names>
</name>
<etal/>
</person-group> <article-title>Parkinson’s disease-cognitive rating scale: a new cognitive scale specific for Parkinson’s disease</article-title>. <source>Mov Disord</source>. <year>2008</year>;<volume>23</volume>(<issue>7</issue>):<fpage>998</fpage>–<lpage>1005</lpage>.</citation>
</ref>
<ref id="bibr20-0891988713481267">
<label>20</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Lovibond</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Lovibond</surname>
<given-names>PF</given-names>
</name>
</person-group>. <source>Manual for the Depression Anxiety Stress Scales</source>. <publisher-loc>Sydney</publisher-loc>: <publisher-name>The Psychology Foundation of Australia, Inc.</publisher-name>; <year>1995</year>.</citation>
</ref>
<ref id="bibr21-0891988713481267">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McNamara</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Durso</surname>
<given-names>R</given-names>
</name>
<name><surname>Harris</surname><given-names>E</given-names></name> 
</person-group>. <article-title>“Machiavellianism” and frontal dysfunction: evidence from Parkinson’s disease (PD)</article-title>. <source>Cogn Neuropsychiatry</source>. <year>2007</year>;<volume>12</volume>(<issue>4</issue>):<fpage>285</fpage>–<lpage>300</lpage>.</citation>
</ref>
<ref id="bibr22-0891988713481267">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McNamara</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Stavitsky</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Durso</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>E.</given-names>
</name>
</person-group> <article-title>The impact of clinical and cognitive variables on social functioning in Parkinson's disease: patient versus examiner estimates</article-title>. <source>Parkinsons Dis</source> <year>2010</year>. <volume>pii 263083</volume>:<fpage>6 pages</fpage>.</citation>
</ref>
<ref id="bibr23-0891988713481267">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McNamara</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Stavitsky</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>E</given-names>
</name>
</person-group>, et al. <article-title>Mood, side of motor symptom onset and pain complaints in Parkinson’s disease</article-title>. <source>Int J Geriatr Psychiatry</source>. <year>2010</year>;<volume>25</volume>(<issue>5</issue>):<fpage>519</fpage>–<lpage>524</lpage>.</citation>
</ref>
<ref id="bibr24-0891988713481267">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Antony</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Bieling</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Cox</surname>
<given-names>BJ</given-names>
</name>
</person-group>, et al. <article-title>Psychometric properties of the 42-item and 21-item versions of the Depression Anxiety Stress Scales (DASS) in clinical groups and a community sample</article-title>. <source>Psychol Assess</source>. <year>1998</year>;<volume>10</volume>(<issue>2</issue>):<fpage>176</fpage>–<lpage>181</lpage>.</citation>
</ref>
<ref id="bibr25-0891988713481267">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crawford</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Henry</surname>
<given-names>JD</given-names>
</name>
</person-group>. <article-title>The Depression Anxiety Stress Scales (DASS): normative data and latent structure in a large non-clinical sample</article-title>. <source>Br J Clin Psychol</source>. <year>2003</year>;<volume>42</volume>(<issue>pt 2</issue>):<fpage>111</fpage>–<lpage>131</lpage>.</citation>
</ref>
<ref id="bibr26-0891988713481267">
<label>26</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Golden</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Freshwater</surname>
<given-names>SM</given-names>
</name>
</person-group>. <source>The Stroop Color and Word Test: A Manual for Clinical and Experimental Uses</source>. <publisher-loc>Chicago, IL</publisher-loc>: <publisher-name>Stoelting Co.</publisher-name>; <year>2002</year>.</citation>
</ref>
<ref id="bibr27-0891988713481267">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Butterfield</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Cimino</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Oelke</surname>
<given-names>LE</given-names>
</name>
</person-group>, et al. <article-title>The independent influence of apathy and depression on cognitive functioning in Parkinson’s disease</article-title>. <source>Neuropsychology</source>. <year>2010</year>;<volume>24</volume>(<issue>6</issue>):<fpage>721</fpage>–<lpage>730</lpage>.</citation>
</ref>
<ref id="bibr28-0891988713481267">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pluck</surname>
<given-names>GC</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>RG</given-names>
</name>
</person-group>. <article-title>Apathy in Parkinson’s disease</article-title>. <source>J Neurol Neurosurg Psychiatry</source>. <year>2002</year>;<volume>73</volume>(<issue>6</issue>):<fpage>636</fpage>–<lpage>642</lpage>.</citation>
</ref>
<ref id="bibr29-0891988713481267">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rabkin</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Ferrando</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>van Gorp</surname>
<given-names>W</given-names>
</name>
</person-group>, et al. <article-title>Relationships among apathy, depression, and cognitive impairment in HIV/AIDS</article-title>. <source>J Neuropsychiatry Clin Neurosci</source>. <year>2000</year>;<volume>12</volume>(<issue>4</issue>):<fpage>451</fpage>–<lpage>457</lpage>.</citation>
</ref>
<ref id="bibr30-0891988713481267">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brück</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Portin</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Lindell</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group> <article-title>Positron emission tomography shows that impaired frontal lobe functioning in Parkinson’s disease is related to dopaminergic hypofunction in the caudate nucleus</article-title>. <source>Neurosci Lett</source>. <year>2001</year>;<volume>311</volume>(<issue>2</issue>):<fpage>81</fpage>–<lpage>84</lpage>.</citation>
</ref>
<ref id="bibr31-0891988713481267">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kirsch-Darrow</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zahodne</surname>
<given-names>LB</given-names>
</name>
<name>
<surname>Marsiske</surname>
<given-names>M</given-names>
</name>
</person-group>, et al. <article-title>The trajectory of apathy after deep brain stimulation: from pre-surgery to 6 months post-surgery in Parkinson’s disease</article-title>. <source>Parkinsonism Rel Disord</source>. <year>2011</year>;<volume>17</volume>(<issue>3</issue>):<fpage>182</fpage>–<lpage>188</lpage>.</citation>
</ref>
<ref id="bibr32-0891988713481267">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oguru</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tachibana</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Toda</surname>
<given-names>K</given-names>
</name>
</person-group>, et al. <article-title>Apathy and depression in Parkinson disease</article-title>. <source>J Geriatr Psychiatry Neurol</source>. <year>2010</year>;<volume>23</volume>(<issue>1</issue>):<fpage>35</fpage>–<lpage>41</lpage>.</citation>
</ref>
<ref id="bibr33-0891988713481267">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Starkstein</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Merello</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Jorge</surname>
<given-names>R</given-names>
</name>
</person-group>, et al. <article-title>The syndromal validity and nosological position of apathy in Parkinson’s disease</article-title>. <source>Mov Disord</source>. <year>2009</year>;<volume>24</volume>(<issue>8</issue>):<fpage>1211</fpage>–<lpage>1216</lpage>.</citation>
</ref>
<ref id="bibr34-0891988713481267">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Drijgers</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Dujardin</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Reijnders</surname>
<given-names>JS</given-names>
</name>
</person-group>, et al. <article-title>Validation of diagnostic criteria for apathy in Parkinson’s disease</article-title>. <source>Parkinsonism Rel Disord</source>. <year>2010</year>;<volume>16</volume>(<issue>10</issue>):<fpage>656</fpage>–<lpage>660</lpage>.</citation>
</ref>
<ref id="bibr35-0891988713481267">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cummings</surname>
<given-names>JL</given-names>
</name>
</person-group>. <article-title>The Neuropsychiatric Inventory: assessing psychopathology in dementia patients</article-title>. <source>Neurol</source>. <year>1997</year>;<volume>48</volume>(<issue>suppl 6</issue>):<fpage>S10</fpage>–<lpage>S16</lpage>.</citation>
</ref>
<ref id="bibr36-0891988713481267">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pedersen</surname>
<given-names>KF</given-names>
</name>
<name>
<surname>Alves</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Aarsland</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Larsen</surname>
<given-names>JP</given-names>
</name>
</person-group>. <article-title>Occurrence and risk factors for apathy in Parkinson disease: a 4-year prospective longitudinal study</article-title>. <source>J Neurol Neurosurg Psychiatry</source>. <year>2009</year>;<volume>80</volume>(<issue>11</issue>):<fpage>1279</fpage>–<lpage>1282</lpage>.</citation>
</ref>
<ref id="bibr37-0891988713481267">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pedersen</surname>
<given-names>KF</given-names>
</name>
<name>
<surname>Alves</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Brønnick</surname>
<given-names>K</given-names>
</name>
</person-group>, et al. <article-title>Apathy in drug-naïve patients with incident Parkinson’s disease: the Norwegian ParkWest study</article-title>. <source>J Neurol</source>. <year>2010</year>;<volume>257</volume>(<issue>2</issue>):<fpage>217</fpage>–<lpage>223</lpage>.</citation>
</ref>
<ref id="bibr38-0891988713481267">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dujardin</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Sockeel</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Devos</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group> <article-title>Characteristics of apathy in Parkinson’s disease</article-title>. <source>Mov Disord</source>. <year>2007</year>;<volume>22</volume>(<issue>6</issue>):<fpage>778</fpage>–<lpage>784</lpage>.</citation>
</ref>
<ref id="bibr39-0891988713481267">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dujardin</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Sockeel</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Delliaux</surname>
<given-names>M</given-names>
</name>
</person-group>, et al. <article-title>Apathy may herald cognitive decline and dementia in Parkinson’s Disease</article-title>. <source>Mov Disord</source>. <year>2009</year>;<volume>24</volume>(<issue>16</issue>):<fpage>2391</fpage>–<lpage>2397</lpage>.</citation>
</ref>
<ref id="bibr40-0891988713481267">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sockeel</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Dujardin</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Devos</surname>
<given-names>D</given-names>
</name>
</person-group>, et al. <article-title>The Lille Apathy Rating Scale (LARS), a new instrument for detecting and quantifying apathy: validation in Parkinson’s disease</article-title>. <source>J Neurol Neurosurg Psychiatry</source>. <year>2006</year>;<volume>77</volume>(<issue>5</issue>):<fpage>579</fpage>–<lpage>584</lpage>.</citation>
</ref>
<ref id="bibr41-0891988713481267">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Robert</surname>
<given-names>PH</given-names>
</name>
<name>
<surname>Clairet</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Benoit</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group> <article-title>The apathy inventory: assessment of apathy and awareness in Alzheimer’s disease, Parkinson’s disease and mild cognitive impairment</article-title>. <source>Int J Geriatr Psychiatry.</source> <year>2002</year>;<volume>17</volume>(<issue>12</issue>):<fpage>1099</fpage>–<lpage>1105</lpage>.</citation>
</ref>
<ref id="bibr42-0891988713481267">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martinez-Corral</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pagonabarraga</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Llebaria</surname>
<given-names>G</given-names>
</name>
<etal/>
</person-group> <article-title>Facial emotion recognition impairment in patients with Parkinson’s Disease and isolated apathy. [published online ahead of print July 28, 2010]</article-title> <source>Parkinsons Dis</source>. <comment>Article ID 930627</comment>.</citation>
</ref>
<ref id="bibr43-0891988713481267">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Levy</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Czernecki</surname>
<given-names>V</given-names>
</name>
</person-group>. <article-title>Apathy and the basal ganglia</article-title>. <source>J Neurol</source>. <year>2006</year>;<volume>253</volume>(<issue>suppl 7</issue>):<fpage>54</fpage>–<lpage>61</lpage>.</citation>
</ref>
<ref id="bibr44-0891988713481267">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cramer</surname>
<given-names>CK</given-names>
</name>
<name>
<surname>Friedman</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Amick</surname>
<given-names>MM</given-names>
</name>
</person-group>. <article-title>Olfaction and apathy in Parkinson’s disease</article-title>. <source>Parkinsonism Rel Disord</source>. <year>2010</year>;<volume>16</volume>(<issue>2</issue>):<fpage>124</fpage>–<lpage>126</lpage>.</citation>
</ref>
<ref id="bibr45-0891988713481267">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Agid</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Cervera</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Hirsch</surname>
<given-names>E</given-names>
</name>
<etal/>
</person-group> <article-title>Biochemistry of Parkinson’s disease 28 years later: a critical review</article-title>. <source>Mov Disord</source>. <year>1989</year>;<volume>4</volume>(<issue>suppl 1</issue>):<fpage>S126</fpage>–<lpage>S144</lpage>.</citation>
</ref>
<ref id="bibr46-0891988713481267">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Isella</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Melzi</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Grimaldi</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group> <article-title>Clinical, neuropsychological, and morphometric correlates of apathy in Parkinson’s disease</article-title>. <source>Mov Disord</source>. <year>2002</year>;<volume>17</volume>(<issue>2</issue>):<fpage>366</fpage>–<lpage>371</lpage>.</citation>
</ref>
<ref id="bibr47-0891988713481267">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marsden</surname>
<given-names>CD</given-names>
</name>
</person-group>. <article-title>Parkinson’s disease</article-title>. <source>Lancet</source>. <year>1990</year>;<volume>335</volume>(<issue>8695</issue>):<fpage>948</fpage>–<lpage>952</lpage>.</citation>
</ref>
<ref id="bibr48-0891988713481267">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Delgado</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Reward-related responses in the human striatum</article-title>. <source>Ann N Y Acad Sci</source>. <year>2007</year>;<volume>1104</volume>:<fpage>70</fpage>–<lpage>88</lpage>.</citation>
</ref>
<ref id="bibr49-0891988713481267">
<label>49</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haaxma</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Helmich</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Borm</surname>
<given-names>GF</given-names>
</name>
</person-group>, et al. <article-title>Side of symptom onset affects motor dysfunction in Parkinson’s disease</article-title>. <source>Neuroscience</source>. <year>2010</year>;<volume>170</volume>(<issue>4</issue>):<fpage>1282</fpage>–<lpage>1285</lpage>.</citation>
</ref>
<ref id="bibr50-0891988713481267">
<label>50</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kempster</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Gibb</surname>
<given-names>WRG</given-names>
</name>
<name>
<surname>Stern</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Lees</surname>
<given-names>AJ</given-names>
</name>
</person-group>. <article-title>Asymmetry of substantia nigra neuronal loss in Parkinson’s disease and its relevance to the mechanism of levodopa related motor fluctuations</article-title>. <source>J Neurol Neurosurg Psychiatry</source>. <year>1989</year>;<volume>52</volume>(<issue>1</issue>):<fpage>72</fpage>–<lpage>76</lpage>.</citation>
</ref>
<ref id="bibr51-0891988713481267">
<label>51</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dethy</surname>
<given-names>S</given-names>
</name>
<name>
<surname>van Blercom</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Damhaut</surname>
<given-names>P</given-names>
</name>
</person-group>, et al. <article-title>Asymmetry of basal ganglia glucose metabolism and dopa responsiveness in parkinsonism</article-title>. <source>Mov Disord</source>. <year>1998</year>;<volume>13</volume>(<issue>2</issue>):<fpage>275</fpage>–<lpage>280</lpage>.</citation>
</ref>
<ref id="bibr52-0891988713481267">
<label>52</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Djaldetti</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ziv</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Melamed</surname>
<given-names>E</given-names>
</name>
</person-group>. <article-title>The mystery of motor asymmetry in Parkinson’s disease</article-title>. <source>Lancet Neurol</source>. <year>2006</year>;<volume>5</volume>(<issue>9</issue>):<fpage>796</fpage>–<lpage>802</lpage>.</citation>
</ref>
<ref id="bibr53-0891988713481267">
<label>53</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Djaldetti</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Treves</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Ziv</surname>
<given-names>I</given-names>
</name>
</person-group>, et al. <article-title>Use of a single [123I]-FP-CIT SPECT to predict the severity of clinical symptoms of Parkinson disease</article-title>. <source>Neurol Sci</source>. <year>2009</year>;<volume>30</volume>(<issue>4</issue>):<fpage>301</fpage>–<lpage>305</lpage>.</citation>
</ref>
<ref id="bibr54-0891988713481267">
<label>54</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Djaldetti</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Lorberboym</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Karmon</surname>
<given-names>Y</given-names>
</name>
</person-group>, et al. <article-title>Residual striatal dopaminergic nerve terminals in very long-standing Parkinson’s disease: a single photon emission computed tomography imaging study</article-title>. <source>Mov Disord</source>. <year>2011</year>;<volume>26</volume>(<issue>2</issue>):<fpage>327</fpage>–<lpage>330</lpage>.</citation>
</ref>
<ref id="bibr55-0891988713481267">
<label>55</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morrish</surname>
<given-names>PK</given-names>
</name>
<name>
<surname>Sawle</surname>
<given-names>GV</given-names>
</name>
<name>
<surname>Brooks</surname>
<given-names>DJ</given-names>
</name>
</person-group>. <article-title>Clinical and [18F]dopa PET findings in early Parkinson’s disease</article-title>. <source>J Neurol Neurosurg Psychiatry</source> <year>1995</year>; <volume>59</volume>:<fpage>597</fpage>–<lpage>600</lpage>.</citation>
</ref>
<ref id="bibr56-0891988713481267">
<label>56</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Harris</surname>
<given-names>E</given-names>
</name>
</person-group>. <source>Neurocognition and self-regulation of the agentic self in patients with Parkinson’s disease</source> <comment>(Doctoral dissertation)</comment>. <publisher-name>Boston University</publisher-name>, <publisher-loc>Boston, MA</publisher-loc>, <year>2011</year>.</citation>
</ref>
<ref id="bibr57-0891988713481267">
<label>57</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blakemore</surname>
<given-names>S-J</given-names>
</name>
<name>
<surname>Frith</surname>
<given-names>C</given-names>
</name>
</person-group>. <article-title>Self-awareness and action</article-title>. <source>Curr Opin Neurobiol</source>. <year>2003</year>;<volume>13</volume>(<issue>2</issue>):<fpage>219</fpage>–<lpage>224</lpage>.</citation>
</ref>
<ref id="bibr58-0891988713481267">
<label>58</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frith</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Blakemore</surname>
<given-names>S-J</given-names>
</name>
<name>
<surname>Wolpert</surname>
<given-names>DM</given-names>
</name>
</person-group>. <article-title>Abnormalities in the awareness and control of action</article-title>. <source>Philos Trans R Soc Lon B Biol Sci</source>. <year>2000</year>;<volume>355</volume>(<issue>1404</issue>):<fpage>1771</fpage>–<lpage>1788</lpage>.</citation>
</ref>
<ref id="bibr59-0891988713481267">
<label>59</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gallagher</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Philosophical conceptions of the self: implications for cognitive science</article-title>. <source>Trends Cogn Sci</source>. <year>2000</year>;<volume>4</volume>(<issue>1</issue>):<fpage>14</fpage>–<lpage>21</lpage>.</citation>
</ref>
<ref id="bibr60-0891988713481267">
<label>60</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haggard</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>Human volition: towards a neuroscience of will</article-title>. <source>Nat Rev Neurosci</source>. <year>2008</year>;<volume>9</volume>(<issue>12</issue>):<fpage>934</fpage>–<lpage>946</lpage>.</citation>
</ref>
<ref id="bibr61-0891988713481267">
<label>61</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haggard</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Clark</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Intentional action: conscious experience and neural prediction</article-title>. <source>Conscious Cogn</source>. <year>2003</year>;<volume>12</volume>(<issue>4</issue>):<fpage>695</fpage>–<lpage>707</lpage>.</citation>
</ref>
<ref id="bibr62-0891988713481267">
<label>62</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haggard</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Clark</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kalogeras</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Voluntary action and conscious awareness</article-title>. <source>Nat Neurosci</source>. <year>2002</year>;<volume>5</volume>(<issue>4</issue>):<fpage>382</fpage>–<lpage>385</lpage>.</citation>
</ref>
<ref id="bibr63-0891988713481267">
<label>63</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>McNamara</surname>
<given-names>P</given-names>
</name>
</person-group>. <source>The Cognitive Neuropsychiatry of Parkinson’s Disease</source>. <publisher-loc>Cambridge, MA</publisher-loc>: <publisher-name>The MIT Press</publisher-name>; <year>2011</year>.</citation>
</ref>
<ref id="bibr64-0891988713481267">
<label>64</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moore</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Haggard</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>Awareness of action: inference and prediction</article-title>. <source>Conscious Cogn</source>. <year>2008</year>;<volume>17</volume>(<issue>1</issue>):<fpage>136</fpage>–<lpage>144</lpage>.</citation>
</ref>
<ref id="bibr65-0891988713481267">
<label>65</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moore</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Wegner</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Haggard</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>Modulating the sense of agency with external cues</article-title>. <source>Conscious Cogn</source>. <year>2009</year>;<volume>18</volume>(<issue>4</issue>):<fpage>1056</fpage>–<lpage>1064</lpage>.</citation>
</ref>
<ref id="bibr66-0891988713481267">
<label>66</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moore</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Schwingenschuh</surname>
<given-names>P</given-names>
</name>
</person-group>, et al. <article-title>Dopaminergic medication boosts action-effect binding in Parkinson’s disease</article-title>. <source>Neuropsychologia</source>. <year>2010</year>;<volume>48</volume>(<issue>4</issue>):<fpage>1125</fpage>–<lpage>1132</lpage>.</citation>
</ref>
<ref id="bibr67-0891988713481267">
<label>67</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Synofzik</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Vosgerau</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Newen</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Beyond the comparator model: a multifactorial two-step account of agency</article-title>. <source>Conscious Cogn</source>. <year>2008</year>;<volume>17</volume>(<issue>1</issue>):<fpage>219</fpage>–<lpage>239</lpage>.</citation>
</ref>
<ref id="bibr68-0891988713481267">
<label>68</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cooper</surname>
<given-names>RP</given-names>
</name>
<name>
<surname>Schwartz</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Yule</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Shallice</surname>
<given-names>T</given-names>
</name>
</person-group>. <article-title>The simulation of action disorganization in complex activities of daily living</article-title>. <source>Cogn Neuropsychol</source>. <year>2005</year>;<volume>22</volume>(<issue>8</issue>):<fpage>959</fpage>–<lpage>1004</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>